Pseudomonas
Addressing infection, bleeding in lower extremity dermatologic surgeries
Tobramycin inhalation solution safe for bronchiectasis with Pseudomonas aeruginosa
US experiences around 7 million waterborne illnesses annually
Extending ceftolozane-tazobactam infusions may prevent emerging resistance
AI predicts presence of Pseudomonas, MRSA in sputum cultures
Reused, resterilized implantable cardiac devices show similar 2-year outcomes as new
Cefiderocol: A novel siderophore cephalosporin for MDR gram-negative infections
Multidrug-resistant (MDR) gram-negative bacteria continue to present an important threat to public health, and a long-stagnating antibiotic pipeline prompted the launch of the “10 x ’20” initiative by the Infectious Diseases Society of America in 2010. The IDSA called for FDA approval of 10 new systemic antibiotics by the year 2020. This goal has now been met and exceeded, largely through the Generating Antibiotic Incentives Now title of the FDA Safety and Innovation Act, which permitted fast track and priority review, followed by an additional 5 years of patent exclusivity upon approval, for novel antimicrobials.